All In Biotech

Investigational drug · Phase 2

AB8939

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia.

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "AB8939"

First trial start

2022

Jun 1, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "AB8939", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • Myelodysplastic Syndrome Acute Myeloid Leukemia

Approved drugs for the same conditions: Acute myeloid leukemia · Myelodysplastic syndromes · Hematology and blood cancers · Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "AB8939" as an intervention, largest first.

All trials
  • AB ScienceIndustry

    NCT05211570 · 78 participants (planned) · Start Jun 1, 2022 · Primary completion Aug 2026

    Drug: AB8939; Venetoclax · For: Acute Myeloid Leukemia Refractory; Acute Myeloid Leukemia, in Relapse; Myelodysplastic Syndrome Acute Myeloid Leukemia

    Sites: Houston, Texas; Marseille, France; Athens, Greece · 10 sites in all

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Acute Myeloid Leukemia Refractory

  • ARD103Phase 21 trial

    ARCE Therapeutics, Inc. · Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, MDS (Myelodysplastic Syndrome)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.